bluebird bio Inc to Provide Updated Findings from Reported Case of Acute Myeloid Leukemia (AML) in LentiGlobin for Sickle Cell Disease (SCD) Gene Therapy Program - Conference Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the bluebird bio conference call. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Ms. Liz Pingpank. Ma'am, the floor is yours.
Thank you. Good morning, everyone, and thank you for joining today's call to discuss an update into the investigation of recent adverse events reported in our HGB-206 study. On today's call, Nick and Philip will discuss the updates and will be joined in Q&A by Dave and Chip.
Before we begin, we would like to remind everyone that as part of this conversation, we will be making statements about ongoing investigation into 2 safety events in the HGB-206 clinical study disclosed on February 16, including our plans for further investigation and potential regulatory interactions in sickle cell disease and beta thalassemia. These statements constitute forward-looking statements and represent our views as of today and should not be relied
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
